Fundraising Fox
/Companies
Sign in

Splice Bio

Barcelona, ES · 58 employees on LinkedIn · 10 known investors

Find your way into Splice Bio

Sign up to see every warm intro you have to Splice Bio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Splice Bio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes. The company is currently in clinical stages, with its lead program targeting Stargardt Disease.

BiotechDeep TechDigital Health

Founders & leadership

DVDr. Vila-Perelló
Dr. Vila-PerellóCEO
DF
Dr. FrutosCo-founder

Investors · 10

Novartis Venture Fund✓ confirmed by Splice BioBasel · $5M – $25M

How we know: Novartis Venture Fund's portfolio page · the company's own site · a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us

Roche Venture Fund✓ confirmed by Splice BioBasel · $648K – $3.2M

How we know: Roche Venture Fund's portfolio page · the company's own site · a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us

Sanofi Ventures✓ confirmed by Splice BioCambridge · $5M

How we know: Sanofi Ventures's portfolio page · the company's own site · a partner's Signal profile · funding news · the VCSheet dataset · Not right? Tell us

Ysios Capital✓ confirmed by Splice BioBarcelona · $5.4M – $21.6M

How we know: Ysios Capital's portfolio page · the company's own site · a partner's Signal profile · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Criteria Bio Ventureslisted by Criteria Bio VenturesBarcelona
New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40M

How we know: a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us

EQT Life SciencesreportedAmsterdam · $11M – $66M

How we know: funding news · Not right? Tell us

InkefreportedAmsterdam

How we know: a partner's Signal profile · Not right? Tell us

UCB VenturesreportedBrussels

How we know: funding news · Not right? Tell us

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 3

AskBioAskBio is a gene therapy company developing adeno-associated virus (AAV)-based genetic medicines for rare and other diseases, with clinical programs such as AB-1009 for late-onset Pompe disease. It operates as a wholly owned, independent subsidiary of Bayer AG.
Senti BiosciencesSenti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells. The company is a clinical-stage biotech firm leveraging proprietary platform technology across multiple cell types and modalities.
BridgebioBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.

Companies working in the same space as Splice Bio.

In the news

SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines - Splice Biosplice.bio · Jun 2025News - Splice Biosplice.bio · May 2025SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline - Splice Biosplice.bio · Feb 2022Splice Bio announces research funding by Cystic Fibrosis Foundation to develop novel AAV vectors - Splice Biosplice.bio · Dec 2020

Frequently asked questions

What does Splice Bio do?
SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes. The company is currently in clinical stages, with its lead program targeting Stargardt Disease.
Who founded Splice Bio?
Splice Bio was founded by Dr. Vila-Perelló, Dr. Frutos.
Who are Splice Bio's investors?
Splice Bio's investors include Asabys Partners, Novartis Venture Fund, Roche Venture Fund, Sanofi Ventures, Ysios Capital, Criteria Bio Ventures, New Enterprise Associates (NEA), EQT Life Sciences and 2 more.
Where is Splice Bio headquartered?
Splice Bio is headquartered in Barcelona, ES.